
This KEYTRUDA Combination Is Approved for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
This KEYTRUDA Combination Is the First Immunotherapy Regimen Approved for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)